"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021. On top of that, new partnerships, like COVAX, for up to 466 million doses in 2022 and discussions with new governments in Asia, Middle East, Africa and Latin America, make us believe that our total advance purchase agreements for 2022 should be higher than those in 2021.”

We announced last week that we have decided to invest to increase our 2020 supply to up to 3 billion doses. Let me share with you why we decided to recommend to our Board to invest at that scale? First, let’s talk about the science of SARS-CoV-2 virus. New variants of concern continue to emerge around the world, and we believe that over the next six months at the southern hemisphere and its fall and winter, we could see variants of concern emerge. We expect for a while now that we believe booster shots will be needed as we believe that the virus is not going away. We also believe, from a scientific standpoint, that the highest efficacy booster over time will be provided by multi-variant-specific booster...
More importantly, as we are talking to governors around the world in the West and in the East, in the North and in the South, we’re hearing loud and clear from the market, supply us with more mRNA vaccine for primary series and supply us with more mRNA vaccine in the future for boosters for 2022 and 2023. There is a big shift versus what the market perceived six or nine or 12 months ago when protein vaccine or adeno vaccines were thought to be the answer to the pandemic. We believe it has become an mRNA market for COVID-19 vaccine....
We believe we will bring to market several more products in the next two years, that will add to the market demand for COVID-19 boosters for years through vaccine as we discussed at our Vaccine Day and our goal is for the seasonal flu vaccine combined with the COVID variant booster in a single dose product.

Another piece of feedback we’re hearing from the market is that, Moderna has the best-in-class mRNA vaccine, shipment of minus 20 Celsius and storage, not minus 70 Celsius. Small cartons of 100 doses. Storage up to six months in standard freezer and four weeks in a regular refrigerated temperatures. The only authorized mRNA vaccine that does not require on-site dilution. We believe this is an even more important feature today, that will be more in the future in 2021 and 2022 and 2023 as we move to a booster market and decentralized in pharmacies and at doctor’s office. We believe we have the best mRNA vaccine authorized and we wanted to improve our product, continue to have the best-in-class products of the mRNA market.

Let me share our perspective on yesterday afternoon announcement by the United States Trade Ambassador, that the US government will support waiving intellectual property protection for COVID-19 vaccines. We believe this will not help supply more mRNA vaccines to the world any faster in 2021 or in 2022, which is the most critical time of the pandemic.
There is no idle mRNA manufacturing capacity in the world.

• Moderna (NASDAQ:MRNA) expects to launch a single-dose COVID-19 vaccine in India next year, the Indian news agency PTI reports.
• The company is in dialogue with several firms including India-based pharmaceutical company Cipla to make the product available in 2022.
• Moderna has reportedly informed the Indian authorities that it would not have surplus COVID-19 vaccines to share with the country in 2021.

reteiP schreef: ↑4 juni 2021, 19:36 $200 mijlpaal vandaag

reteiP schreef: ↑8 juni 2021, 15:55 Misschien post ik hier wel nog updates, maar ik heb mijn positie vandaag volledig verkocht aan iets meer dan $220 bij opening.
CAGR van 2 aankopen en 1 verkoop komt op 207%, op naar een volgende investering met zo'n rendement.

SparSpaar schreef: ↑1 maart 2021, 13:54 Voor mijn gemoedsrust mijn posities in Moderna volledig verkocht, zo zie ik mijn winst (99$ - > 160$) eveneens verzekerd.
Het vet zal voor de brouwers van deze giftige cocktails zeker stilaan van de soep zijn ?

• Today, Moderna announced more details to support the vaccine’s efficacy against additional coronavirus variants including the Delta variant.
• According to the company, the lab-based studies on serum samples from eight participants who were fully immunized with the vaccine indicated there was only a modest reduction in neutralizing antibody titers against the Delta (2.1-fold) variant relative to the original COVID-19 strain